Showing results (421-430 of 554) with videos related to
Sort By:
Pageof 56
Cancer Immunology Research|May 28, 2015
Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell CarcinomaMarcella Callea, Laurence Albiges, Mamta Gupta, et al.Gastrointestinal Endoscopy|February 16, 2013
Pancreatic and biliary stents, Patrick R Pfau, Douglas K Pleskow, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 1997
Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicityJ A Sosman, F R Aronson, M Sznol, et al.Journal for Immunotherapy of Cancer|September 12, 2025
Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047Meredith M Regan, Paolo A Ascierto, Evan J Lipson, et al.The Lancet. Oncology|December 11, 2012
Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort studyFabio A B Schutz, Mark M Pomerantz, Kathryn P Gray, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2008
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanomaJeffrey A Sosman, Carole Carrillo, Walter J Urba, et al.Journal for Immunotherapy of Cancer|March 31, 2023
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminologyJarushka Naidoo, Catherine Murphy, Michael B Atkins, et al.Cancer Medicine|July 19, 2017
A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation statusBenjamin Izar, William Sharfman, F Stephen Hodi, et al.JAMIA Open|July 10, 2025
Utilizing Immuno-Oncology registry data for enhanced non-small cell lung cancer treatment predictionsYili Zhang, Shaked Lev-Ari, Jacob Zaemes, et al.Molecular and Cellular Biology|July 26, 2002
Microarray analyses during adipogenesis: understanding the effects of Wnt signaling on adipogenesis and the roles of liver X receptor alpha in adipocyte metabolismSarah E Ross, Robin L Erickson, Isabelle Gerin, et al.Pageof 56